FS-2

• UNSPSC Description:

  FS-2 is a potent and specific L-type CaV channel inhibitor. FS-2 inhibits high K+ or glucose induced L-type Ca2+ influx in RIN beta cells[1].

• Target Antigen:

  Calcium Channel

• Type:

  Peptides

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/fs-2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CSSC[C@@H](C(N1[C@@H](CCC1)C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N4[C@@H](CCC4)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@H]6CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC7=O)C(N[C@@H](CC8=CC=C(C=C8)O)C(N[C@@H](CO)C(N[C@@H](CC9=CNC=N9)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N%10[C@@H](CCC%10)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(O)=O)=O)=O)NC%11=O)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CSSC[C@@H](C(N[C@@H](CCCCN)C(NCC(N[C@@H](CC(O)=O)C(N[C@H]%11CCCNC(N)=N)=O)=O)=O)=O)NC%12=O)C(N[C@@H](CC%13=CC=C(C=C%13)O)C(N[C@@H](CCCCN)C(N[C@@H](CCSC)C(N[C@@H](CC%14=CC=CC=C%14)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC%15=CNC=N%15)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC%16=CC=C(C=C%16)O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CSSC[C@@H]%12NC6=O)C(NC7)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N

• Molecular Weight:

  7018.06

• References & Citations:

  [1]Schweitz H, et al. Purification and pharmacological characterization of peptide toxins from the black mamba (Dendroaspis polylepis) venom. Toxicon. 1990;28(7):847-56.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported